BioNTech: ‘No evidence’ COVID vaccine needs adapting for variants
Al Jazeera
The German company says the shot it developed with US pharmaceutical giant Pfizer does not require modifications for now.
German company BioNTech has said its COVID-19 vaccine, developed in collaboration with pharmaceutical giant Pfizer, does not require modifications to protect people against key variants of the virus currently in circulation. “To date, there is no evidence that an adaptation of BioNTech’s current COVID-19 vaccine against key identified emerging variants is necessary,” the company said in a statement on Monday. It added that it had nevertheless developed “a comprehensive strategy to address these variants should the need arise in the future”.
Agreement greeted with relief in Lebanon and beyond, with some pushing for ‘urgent steps’ to end Israel’s war in Gaza.
Rami Khouri on why the Lebanon ceasefire negotiations may turn into another Western-led, carving up of the Middle East.
Lockdown in the capital lifted after protesters, who forced their way into city on Tuesday amid deadly clashes, cleared.
People quick to start making their way back to homes amid signs that Israel-Hezbollah truce is holding.
Punia, who was at the forefront of protests against former wrestling body chief Brij Bhushan Singh, says he is innocent.
Man City manager admits his team are defensively ‘not stable’ after conceding three goals in 15 minutes in the Champions League.
As a wave of election upsets batters the region, the Southern African country could be next.
US president-elect taps Jamieson Greer and Kevin Hassett as trade representative and top economic adviser, respectively.
These were the key developments on the 1,006th day of Russia’s war on Ukraine.
The S&P 500 rises 0.57 percent after US president-elect’s tariff announcements roil European and Asian markets.
Relations between powerful vice president and president continue to deteriorate, as investigators summon Duterte.